ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,315Medicare Part D Prescriptions Filled, Including Refills

Rank: 23 out of 262

$422K Total Retail Price of All Prescriptions

Rank: 42 out of 262

590 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Dakota
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 590 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

4% of this provider’s 590 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 8,975 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Dakota
LISINOPRIL 629 556 1 3
SIMVASTATIN 447 422 2 1
FUROSEMIDE 428 388 3 4
AMLODIPINE BESYLATE 362 347 4 6
HYDROCHLOROTHIAZIDE 361 340 5 7
OMEPRAZOLE 338 263 6 5
METOPROLOL TARTRATE 330 306 7 8
LEVOTHYROXINE SODIUM 311 287 8 2
POTASSIUM CHLORIDE 248 235 9 10
ATORVASTATIN CALCIUM 239 203 10 13
METFORMIN HCL 220 187 11 9
SERTRALINE HCL 190 183 12 14
METOPROLOL SUCCINATE 185 169 13 11
WARFARIN SODIUM 176 149 14 12
ATENOLOL 150 134 15 16
TAMSULOSIN HCL 141 136 16 25
ALLOPURINOL 134 134 17 22
TRAMADOL HCL 129 96 18 18
LOSARTAN POTASSIUM 128 110 19 17
DONEPEZIL HCL 123 123 20 23
JANTOVEN 107 77 21 39
GABAPENTIN 105 92 22 19
CRESTOR 102 102 23 30
CARVEDILOL 98 86 24 31
CITALOPRAM HBR 94 93 25 20
ISOSORBIDE MONONITRATE ER 93 92 26 33
GLIMEPIRIDE 90 74 27 45
LISINOPRIL-HYDROCHLOROTHIAZIDE 82 71 28 24
DIOVAN 78 78 29 47
ZOLPIDEM TARTRATE 77 71 30 26
SPIRONOLACTONE 75 43 31 58
ALENDRONATE SODIUM 70 33 32 21
DILTIAZEM ER 69 67 33 75
INSULIN SYRINGE 68 57 34 85
FLUTICASONE PROPIONATE 67 56 35 48
TRAZODONE HCL 65 61 36 36
PRAVASTATIN SODIUM 63 63 37 41
DIGOXIN 61 58 38 28
RISPERIDONE 58 58 39 50
LIPITOR 52 34 40 96
LANTUS 51 51 41 51
ROPINIROLE HCL 51 46 41 95
GEMFIBROZIL 50 46 43 92
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 29, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.